First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study | Genetics and Genomics | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Lynch  TJ, Bell  DW, Sordella  R,  et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;350(21):2129-2139.PubMedGoogle ScholarCrossref
2.
Paez  JG, Jänne  PA, Lee  JC,  et al.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;304(5676):1497-1500.PubMedGoogle ScholarCrossref
3.
Mok  TS, Wu  YL, Thongprasert  S,  et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.  N Engl J Med. 2009;361(10):947-957.PubMedGoogle ScholarCrossref
4.
Han  JY, Park  K, Kim  SW,  et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.  J Clin Oncol. 2012;30(10):1122-1128.PubMedGoogle ScholarCrossref
5.
Mitsudomi  T, Morita  S, Yatabe  Y,  et al; West Japan Oncology Group.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.  Lancet Oncol. 2010;11(2):121-128.PubMedGoogle ScholarCrossref
6.
Maemondo  M, Inoue  A, Kobayashi  K,  et al; North-East Japan Study Group.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.  N Engl J Med. 2010;362(25):2380-2388.PubMedGoogle ScholarCrossref
7.
Zhou  C, Wu  YL, Chen  G,  et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.  Lancet Oncol. 2011;12(8):735-742.PubMedGoogle ScholarCrossref
8.
Costa  C, Molina  MA, Drozdowskyj  A,  et al.  The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.  Clin Cancer Res. 2014;20(7):2001-2010.PubMedGoogle ScholarCrossref
9.
Sequist  LV, Yang  JC, Yamamoto  N,  et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.  J Clin Oncol. 2013;31(27):3327-3334.PubMedGoogle ScholarCrossref
10.
Jackman  D, Pao  W, Riely  GJ,  et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.  J Clin Oncol. 2010;28(2):357-360.PubMedGoogle ScholarCrossref
11.
Miller  AB, Hoogstraten  B, Staquet  M, Winkler  A.  Reporting results of cancer treatment.  Cancer. 1981;47(1):207-214.PubMedGoogle ScholarCrossref
12.
Therasse  P, Arbuck  SG, Eisenhauer  EA,  et al.  New guidelines to evaluate the response to treatment in solid tumours.  J Natl Cancer Inst. 2000;92(3):205-216.PubMedGoogle ScholarCrossref
13.
Eisenhauer  EA, Therasse  P, Bogaerts  J,  et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).  Eur J Cancer. 2009;45(2):228-247.PubMedGoogle ScholarCrossref
14.
Yun  CH, Mengwasser  KE, Toms  AV,  et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.  Proc Natl Acad Sci U S A. 2008;105(6):2070-2075.PubMedGoogle ScholarCrossref
15.
Riely  GJ, Kris  MG, Zhao  B,  et al.  Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.  Clin Cancer Res. 2007;13(17):5150-5155.PubMedGoogle ScholarCrossref
16.
Oxnard  GR, Lo  P, Jackman  DM,  et al.  Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR mutant lung cancer.  J Clin Oncol. 2012;30(suppl):abstr 7547.Google Scholar
17.
Nishie  K, Kawaguchi  T, Tamiya  A,  et al.  Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.  J Thorac Oncol. 2012;7(11):1722-1727.PubMedGoogle ScholarCrossref
18.
NCCN Guidelines Version 1.2015. Non-Small Cell Lung Cancer. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 11, 2015.
19.
Ou  SH, Jänne  PA, Bartlett  CH,  et al.  Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.  Ann Oncol. 2014;25(2):415-422.PubMedGoogle ScholarCrossref
20.
Kim  Y, Ko  J, Cui  Z,  et al.  The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.  Mol Cancer Ther. 2012;11(3):784-791.PubMedGoogle ScholarCrossref
21.
Soria  J, Wu  Y, Nakagawa  K,  et al.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.  Lancet Oncol. 2015;16(8):990-998.Google ScholarCrossref
22.
Oxnard  GR, Arcila  ME, Sima  CS,  et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.  Clin Cancer Res. 2011;17(6):1616-1622.PubMedGoogle ScholarCrossref
23.
Wu  YL, Lee  JS, Thongprasert  S,  et al.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.  Lancet Oncol. 2013;14(8):777-786.PubMedGoogle ScholarCrossref
24.
Mok  T, Wu  YL, Lee  JS,  et al.  Detection and dynamic changes of EGFR mutations from circulating tumour DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.  Clin Cancer Res. 2015;21(14):3196-3203.PubMedGoogle ScholarCrossref
Original Investigation
March 2016

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study

Author Affiliations
  • 1Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 2Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
  • 3Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
  • 4Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
  • 5Chang Gung University College of Medicine, Kaohsiung City, Taiwan
  • 6Division of Medical Oncology, Chulalongkorn University, Bangkok, Thailand
  • 7Department of Chest Medicine, Taipei Veteran General Hospital, Taipei, Taiwan
  • 8School of Medicine, National Yang-Ming University, Taipei, Taiwan
  • 9Department of Haematology and Medical Oncology, Seoul National University Bundang Hospital, Bundang, Korea
  • 10Seoul St Mary’s Hospital, Seoul, Korea
  • 11Department of Chemical Pathology, Chinese University of Hong Kong, Hong Kong
  • 12F. Hoffmann–La Roche Ltd, Basel, Switzerland
  • 13Roche Products Pty Ltd, Dee Why, Australia
  • 14State Key Laboratory of South China, Hong Kong Cancer Institute, Chinese University of Hong Kong, Sha Tin, Hong Kong
JAMA Oncol. 2016;2(3):305-312. doi:10.1001/jamaoncol.2015.4921
Abstract

Importance  Continuing molecularly targeted treatment beyond disease progression in non–small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses, highlighting the challenge to identify whether progression is the optimal time to switch treatment.

Objective  To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy.

Design, Setting, and Participants  ASPIRATION (Asian Pacific trial of Tarceva as first-line in EGFR mutation) was a phase 2, open-label, single-arm study conducted from 2011 to 2012 in 23 centers in Hong Kong, Korea, Taiwan, and Thailand of adults with stage IV, EGFR mutation–positive NSCLC, with ECOG performance status 0 to 2.

Interventions  Patients received erlotinib 150 mg/d orally until disease progression, after which erlotinib therapy could be continued at patient and/or investigator discretion.

Main Outcomes and Measures  The primary end point was progression-free survival (PFS1; time to Response Evaluation Criteria in Solid Tumours 1.1 progression or death). Secondary end points included PFS2 (time to off-erlotinib progression if erlotinib therapy was extended beyond progression at patient and/or investigator discretion), objective response rate, disease control rate, overall survival, and safety. The use of plasma-based assessment of EGFR mutations was also investigated.

Results  Of 359 patients screened, 208 were enrolled. Median follow-up was 11.3 (95% CI, 10.9-13.0) months. Of the 207 intent-to-treat patients (62.3% female; median age, 60.8 [range, 28-89] y), 176 had a PFS1 event (171 progression and 5 deaths); of these, 78 discontinued and 93 continued erlotinib therapy following progression. Median PFS1 was 10.8 (95% CI, 9.2-11.1) months. Median PFS1 and PFS2 in the 93 continuing patients was 11.0 (95% CI, 9.2-11.1) and 14.1 (95% CI, 12.2-15.9) months, respectively. Median PFS1 and PFS2 was 11.0 (95% CI, 9.3-12.0) and 14.9 (95% CI, 12.2-17.2) months in patients with exon 19 deletions or L585R mutations. Overall response rate was 66.2%; disease control rate was 82.6%. Median overall survival was 31.0 months (95% CI, 27.3 months to not reached). In the safety population (n = 207) serious adverse events were reported in 27.1%, with events of at least grade 3 experienced by 50.2%. Sensitivity and specificity of plasma-based EGFR mutation analysis was 77% and 92%, respectively.

Conclusions and Relevance  ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation–positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients.

Trial Registration  clinicaltrials.gov Identifier: NCT01310036

×